**Electronic Supplementary Appendix**

**Table S1 Hazard Ratios with and without Inverse Probability Weights**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | **HR (95% CI),****unweighted** | **HR (95% CI),****weighted** | **P-value,****weighted** |
| **Overall Survival** | Modified G/nab-P | Ref | Ref | 0.16 |
| mFOLFIRINOX | 0.77 (0.53-1.12) | 0.76 (0.53-1.11) |
| **Progression Free Survival** | Modified G/nab-P | Ref | Ref | 0.30 |
| mFOLFIRINOX | 0.81 (0.57-1.15) | 0.83 (0.58-1.18) |
| **Time to Treatment Failure** | Modified G/nab-P | Ref | Ref | 0.12 |
| mFOLFIRINOX | 0.78 (0.55-1.10) | 0.75 (0.53-1.07) |

HR: hazard ratio; CI: confidence interval; G/Nab-P: gemcitabine plus nab-paclitaxel; mFOLFIRINOX: modified 5-fluorouracil, leucovorin, irinotecan, oxaliplatin

**Table S2 Multivariate Analysis: Prognostic Factors for Overall Survival**

|  |  |  |
| --- | --- | --- |
| **Variable** | **HR (95% CI)** | **P-value** |
| **Chemotherapy** Modified G/nab-P mFOLFIRINOX | 10.72 (0.50-1.06) | 0.10 |
| **ECOG score** 0 1 2 | 11.43 (0.94-2.18)5.45 (3.06-9.68) | <.001 |
| **Liver metastasis**Yes No | 1.59 (1.03-2.46)1 | 0.04 |
| **Peritoneal carcinomatosis** Yes No | 2.13 (1.41-3.22)1 | <.001 |
| **Albumin** <4 ≥4  | 10.77 (0.52-1.13) | 0.18 |
| **ANC/ALC ratio**  ≤4 >4  | 11.93 (1.36-2.74) | <.001 |
| **Level of CA 19-9a** <59x ULN >59x ULN | 12.03 (1.37-3.02) | <.001 |

HR: hazard ratio; CI: confidence interval; G/Nab-P: gemcitabine plus nab-paclitaxel; mFOLFIRINOX: modified 5-fluorouracil, leucovorin, irinotecan, oxaliplatin; ECOG: Eastern Cooperative Oncology Group; ANC: absolute neutrophil count; ALC: absolute lymphocyte count; ULN: upper limit of the normal range

aThe normal range was 0 to 37 U per milliliter